PRODUCT INFORMATION

Common Name	MG-A271, MGA271
Conjugate	Unconjugated
Synonyms	B7-H3;CD276;B7 homolog 3
Applications	ELISA; Flow Cyt
Endotoxin	Less than 1.0 EU/μg by the LAL method. For <1 EU/mg requirements, please contact us for customization.
Recommended Dilutions	ELISA 1:5000-10000; Flow Cyt 1:100
Formulation & Reconstitution	Lyophilized from sterile PBS, pH 7.4. Normally 5 % – 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Host Species	Humanized
IgG type	Human IgG1 – kappa
Reactivity	Human
Target	B7-H3
Uniprot ID	Q5ZPR3
Description	Anti-B7-H3 (enoblituzumab biosimilar) mAb
Delivery	In Stock
Storage&Shipping	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
Background	Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
Usage	Research use only



Figure 1. ELISA plate pre-coated by 2 μg/ml (100 μl/well) Human B7-H3, mFc-His tagged protein PME100012 can bind Anti-B7-H3 Neutralizing antibody in a linear range of 0.24-31.25 ng/ml.



Figure 2. Flow cytometry analysis with 1μg/mL Anti-B7-H3 (enoblituzumab biosimilar) mAb (BME100010) on Hela cells (Blue histogram) or isotype control mAb on Hela cells (Red histogram).



A

Figure 3. Flow cytometry analysis of antigen binding of anti-human B7-H3 mAb(BME100010).
(A) A clear peak shift of BME100010 was seen compared to the control when incubated with B7-H3-expressing Hela cells, indicating strong binding of BME100010 to B7-H3. Antibodies were incubated at 2 μg/mL.